Literature DB >> 17646057

GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas.

Louise Wideroff1, Thomas L Vaughan, Federico M Farin, Marilie D Gammon, Harvey Risch, Janet L Stanford, Wong-Ho Chow.   

Abstract

BACKGROUND: Polymorphisms in glutathione-S-transferase (GST), N-acetyltransferase (NAT) 1, and CYP1A1 genes have been suggested as susceptibility factors for esophageal and gastric adenocarcinomas, but have not been consistently linked to elevated risks. In a population-based case-control study, we examined risks in relation to polymorphisms of the following genes: GSTP1; GSTM1; GSTT1; NAT1; and CYP1A1.
METHODS: Histologically confirmed incident cases, ages 30-79, were identified in three US locations. Population controls from the same catchment areas were frequency matched to expected age and sex distributions of esophageal and gastric cardia adenocarcinomas. DNA was extracted from buffy coat for PCR-based assays, with interpretable genotyping results obtained from 209 controls, 67 esophageal adenocarcinomas, 60 gastric cardia adenocarcinomas, and 56 noncardia gastric adenocarcinomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated among whites, adjusting for age, sex, and study center.
RESULTS: In all histologic subgroups, ORs were somewhat elevated for the GSTP1 Val/Val genotype (versus Ile/Ile), although 95% CIs included 1.00. The respective ORs for esophageal, cardia, and other gastric adenocarcinomas were 1.73 (0.75-4.02), 1.46 (0.57-3.73), and 1.22 (0.48-3.09). No consistent patterns of elevated risk were associated with the null GSTM1 or GSTT1 genotypes, one or two copies of NAT110 or 11 alleles, or CYP1A1 Val/Val or Ile/Val genotypes (versus Ile/Ile).
CONCLUSIONS: Additional research in larger samples is needed to further assess polymorphisms and their interactions with epidemiologic risk factors, particularly for esophageal adenocarcinoma, which has been increasing markedly in incidence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17646057      PMCID: PMC2268246          DOI: 10.1016/j.cdp.2007.03.004

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  25 in total

1.  Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay.

Authors:  D A Nickerson; R Kaiser; S Lappin; J Stewart; L Hood; U Landegren
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

2.  Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia.

Authors:  M D Gammon; J B Schoenberg; H Ahsan; H A Risch; T L Vaughan; W H Chow; H Rotterdam; A B West; R Dubrow; J L Stanford; S T Mayne; D C Farrow; S Niwa; W J Blot; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1997-09-03       Impact factor: 13.506

3.  Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks.

Authors:  C L Chen; Q Liu; M V Relling
Journal:  Pharmacogenetics       Date:  1996-04

4.  Susceptibility to esophageal cancer and genetic polymorphisms in glutathione S-transferases T1, P1, and M1 and cytochrome P450 2E1.

Authors:  D X Lin; Y M Tang; Q Peng; S X Lu; C B Ambrosone; F F Kadlubar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-11       Impact factor: 4.254

5.  Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia.

Authors:  G C Kabat; S K Ng; E L Wynder
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

6.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

Authors:  M Blum; D M Grant; W McBride; M Heim; U A Meyer
Journal:  DNA Cell Biol       Date:  1990-04       Impact factor: 3.311

7.  Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue.

Authors:  D A Bell; A F Badawi; N P Lang; K F Ilett; F F Kadlubar; A Hirvonen
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

8.  Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.

Authors:  K J Livak; S J Flood; J Marmaro; W Giusti; K Deetz
Journal:  PCR Methods Appl       Date:  1995-06

9.  Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer.

Authors:  Shioto Suzuki; Youko Muroishi; Isao Nakanishi; Yoshio Oda
Journal:  J Gastroenterol       Date:  2004       Impact factor: 7.527

10.  Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma.

Authors:  T L Vaughan; S Davis; A Kristal; D B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1995-03       Impact factor: 4.254

View more
  35 in total

1.  Meta-analysis of the association of CYP1A1 polymorphisms with gastric cancer susceptibility and interaction with tobacco smoking.

Authors:  Fujun Han; Xinsheng Wang; Xuhui Wang; Yongfeng Luo; Wei Li
Journal:  Mol Biol Rep       Date:  2012-06-16       Impact factor: 2.316

2.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

3.  Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility.

Authors:  Ya-Ping Luo; Han-Chun Chen; Md Asaduzzaman Khan; Fang-Zhi Chen; Xin-Xing Wan; Bo Tan; Fang-Dan Ou-Yang; Dian-Zheng Zhang
Journal:  Tumour Biol       Date:  2010-09-29

4.  Role of xenobiotic-metabolizing enzyme gene polymorphisms and interactions with environmental factors in susceptibility to gastric cancer in Kashmir Valley.

Authors:  Manzoor A Malik; Rohit Upadhyay; Rama D Mittal; Showket A Zargar; Dinesh R Modi; Balraj Mittal
Journal:  J Gastrointest Cancer       Date:  2009-06-12

Review 5.  Glutathione S-transferase T1 (GSTT1) gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiologic studies.

Authors:  Bo Chen; Lei Cao; Yong Zhou; Ping Yang; Hong-Wei Wan; Gui-Qing Jia; Liu Liu; Xiao-Ting Wu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

6.  The association between GSTM1 polymorphism and gastric cancer risk: a meta-analysis.

Authors:  Yu Zhu; Qian He; Jing Wang; Hai-Feng Pan
Journal:  Mol Biol Rep       Date:  2011-05-08       Impact factor: 2.316

7.  Ethnic differences in the association of the glutathione S-transferase T1 (GSTT1) null genotype and risk of gastric carcinoma: a systematic review and meta-analysis.

Authors:  Jeongmin Yoon; Myung-Han Hyun; Jong-Pill Yang; Min-Jeong Park; Sungsoo Park
Journal:  Mol Biol Rep       Date:  2014-02-22       Impact factor: 2.316

8.  Effects of Genetic Polymorphisms of Glutathione S-transferase P1 on Helicobacter pylori-associated Gastric Cancer.

Authors:  Jung Mook Kang; Nayoung Kim; Sung-Il Cho; Dong Ho Lee; Young Soo Park; Yu Rim Kim; Ji Hyun Park; Mi Kyoung Lee; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Gut Liver       Date:  2008-06-30       Impact factor: 4.519

9.  Glutathione-S-transferase (GSTM1, GSTT1) and the risk of gastrointestinal cancer in a Korean population.

Authors:  Jin-Mei Piao; Min-Ho Shin; Sun-Seog Kweon; Hee Nam Kim; Jin-Su Choi; Woo-Kyun Bae; Hyun-Jeong Shim; Hyeong-Rok Kim; Young-Kyu Park; Yoo-Duk Choi; Soo-Hyun Kim
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

Review 10.  Glutathione S-transferase M1 null genotype associated with gastric cancer among Asians.

Authors:  Hong Wang; Yong Zhou; Wen Zhuang; Yi-Qiong Yin; Guan-Jian Liu; Tai-Xiang Wu; Xun Yao; Liang Du; Mao-Ling Wei; Xiao-Ting Wu
Journal:  Dig Dis Sci       Date:  2009-09-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.